IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

An Independent Data Monitoring Committee recommended that the ongoing Phase 2 MRD study continue without modification after reviewing all safety data available to date. The recommendation indicates no safety issues requiring a protocol change, but provides no efficacy data or financial impact.